Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
210.5 CHF | +1.20% | +2.43% | +15.28% |
May. 28 | HBM Healthcare Flags NAV Boost from Yellow Jersey-Johnson & Johnson Deal | MT |
May. 23 | HBM Healthcare Investments' Portfolio Company to Buy Laboratorios Biopas Group | MT |
Summary
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The company's profit outlook over the next few years is a strong asset.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
Weaknesses
- With a 2025 P/E ratio at 28.73 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Investment Management & Fund Operators
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+15.28% | 1.59B | D+ | ||
+19.14% | 3.18B | B- | ||
+12.50% | 1.76B | - | - | |
-11.54% | 1.21B | - | - | |
+21.67% | 792M | B+ | ||
+8.22% | 656M | - | ||
+34.39% | 570M | - | D+ | |
+36.49% | 498M | - | - | |
-4.17% | 506M | - | - | |
+86.20% | 357M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- HBMN Stock
- Ratings HBM Healthcare Investments AG